Stratos Wealth Partners LTD. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 0.9% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 139,279 shares of the company’s stock after purchasing an additional 1,280 shares during the period. Johnson & Johnson makes up about 0.6% of Stratos Wealth Partners LTD.’s holdings, making the stock its 26th biggest holding. Stratos Wealth Partners LTD.’s holdings in Johnson & Johnson were worth $22,891,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in JNJ. SYM FINANCIAL Corp increased its stake in shares of Johnson & Johnson by 3.7% in the 4th quarter. SYM FINANCIAL Corp now owns 1,729 shares of the company’s stock worth $272,000 after acquiring an additional 62 shares in the last quarter. Financial Advisors Network Inc. increased its stake in shares of Johnson & Johnson by 2.4% in the 4th quarter. Financial Advisors Network Inc. now owns 2,686 shares of the company’s stock worth $423,000 after acquiring an additional 62 shares in the last quarter. Mather Group LLC. increased its stake in shares of Johnson & Johnson by 0.6% in the 4th quarter. Mather Group LLC. now owns 10,235 shares of the company’s stock worth $1,611,000 after acquiring an additional 62 shares in the last quarter. Cordasco Financial Network increased its stake in shares of Johnson & Johnson by 0.9% in the 1st quarter. Cordasco Financial Network now owns 7,335 shares of the company’s stock worth $1,205,000 after acquiring an additional 62 shares in the last quarter. Finally, Gateway Advisory LLC increased its stake in shares of Johnson & Johnson by 2.1% in the 4th quarter. Gateway Advisory LLC now owns 3,054 shares of the company’s stock worth $481,000 after acquiring an additional 63 shares in the last quarter. 67.25% of the stock is owned by institutional investors.

JNJ stock opened at $165.21 on Tuesday. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a twelve month low of $133.65 and a twelve month high of $173.65. The stock has a market capitalization of $434.95 billion, a price-to-earnings ratio of 25.98, a price-to-earnings-growth ratio of 3.06 and a beta of 0.70. The firm’s fifty day simple moving average is $162.67 and its two-hundred day simple moving average is $156.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Monday, April 19th. The company reported $2.59 EPS for the quarter, topping the Zacks’ consensus estimate of $2.34 by $0.25. The firm had revenue of $22.30 billion for the quarter, compared to analysts’ expectations of $22 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.30 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 7.99 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 8th. Stockholders of record on Tuesday, May 25th will be issued a $1.06 dividend. The ex-dividend date is Monday, May 24th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.01. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio is presently 46.54%.

Several research analysts recently issued reports on the stock. SVB Leerink increased their price target on shares of Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Cantor Fitzgerald raised their price objective on shares of Johnson & Johnson from $180.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, January 26th. JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $157.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, January 27th. Raymond James raised their price objective on shares of Johnson & Johnson from $158.00 to $183.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th. Finally, Morgan Stanley raised their price objective on shares of Johnson & Johnson from $178.00 to $187.00 and gave the company an “overweight” rating in a research note on Wednesday, January 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $182.45.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: Why is the price-sales ratio important?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.